These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 37490245)

  • 1. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
    Yadollahikhales G; Rojas JC
    Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-amyloid Antibody Therapies for Alzheimer's Disease.
    Park KW
    Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Considerations for Amyloid Immunotherapy.
    Foley KE; Wilcock DM
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):709-719. PubMed ID: 36269539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
    Fedele E
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β-targeting immunotherapies for Alzheimer's disease.
    Jin Y; Du Q; Song M; Kang R; Zhou J; Zhang H; Ding Y
    J Control Release; 2024 Nov; 375():346-365. PubMed ID: 39271059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.
    Cummings J; Osse AML; Cammann D; Powell J; Chen J
    BioDrugs; 2024 Jan; 38(1):5-22. PubMed ID: 37955845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More failure with solanezumab - this time in preclinical Alzheimer's disease.
    Doggrell SA
    Expert Opin Biol Ther; 2024 Mar; 24(3):119-123. PubMed ID: 38414336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from antiamyloid-β immunotherapies in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Handb Clin Neurol; 2023; 193():267-292. PubMed ID: 36803816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.